CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study of oregovomab in combination with chemotherapy (paclitaxel and carboplatin) as neo-adjuvant treatment of patients with newly diagnosed advanced epithelial ovarian cancer....
GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation
SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy. Fulzerasib was the first China-developed KRAS G12C...
Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)
The World's First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a randomized controlled clinical...
FINGERPRINT STUDY OF 1000 SINGAPOREANS SHOWS HIGH SELF-MANAGEMENT AND RESILIENCE TRAITS: BRILLIANAIRE
Brillianaire's dermatoglyphic personality and potential testing uncovers major personality traits of Singaporeans across all ages Singapore firm believes such data will help Singapore chart a better future by tapping on its strongest resource: people SINGAPORE, Aug. 23, 2024 /PRNewswire/ -- Brillianaire, Singapore's first self-development consultancy to use dematoglyphics services extensively for children and adults, has for the...
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period ending June 30, 2024, along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "In the first half of 2024, the company has made...
Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market
Today, Getinge announces an agreement to acquire 100% of Paragonix Technologies, Inc., a leading organ transport products and services company in the United States for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million. GOTHENBURG, Sweden, Aug. 23, 2024 /PRNewswire/ -- With the acquisition of Paragonix Technologies – a pioneer and innovator...
Alzheimer’s Association Commends United Kingdom’s Approval of Leqembi, But Condemns Decision to Deny NHS Access
CHICAGO, Aug. 23, 2024 /PRNewswire/ -- The Alzheimer's Association welcomes today's decision by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Leqembi® (lecanemab) for the treatment of Alzheimer's disease. However, while celebrating this milestone — the first Alzheimer's disease modifying treatment approved in the U.K. — the decision...
Ascentage Pharma Announces 2024 Interim Results
ROCKVILLE, Md. and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced its 2024 interim results. During the reporting period, Ascentage Pharma continued to execute its global innovation strategy, having achieved breakthroughs across...
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program Aims to strengthen its oncology portfolio with a novel drug candidate for newly identified hits from HitGen's proprietary DEL...
Ubie Announces Social Impact Framework, Shows Estimated Patient Life Expectancy Impact of 27,000 Years and Approximately $1BN
Ubie has taken the lead in implementing a new standard of measurement to evaluate health and economic impact for global digital health startups The framework uses the pharmaceutical industry's standard of Quality-Adjusted Life Years (QALY) to provide a widely-accepted and transparent impact measurement Preliminary results support the ability of Ubie's AI...
